Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Akebia Therapeutics, Inc., Vifor Pharma Management Ltd., Lupin ...

Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant ...

Calcium-containing phosphate binders are the current mainstay of treatment for hyperphosphatemia in children with chronic kidney disease (CKD), but they are associated with an increased risk of ...

In the U.S., Ardelyx is pursuing approval of tenapanor for the treatment of hyperphosphatemia in adult patients with CKD on dialysis who have had an inadequate response or intolerance to phosphate ...

Hyperphosphatemia is very common in people with chronic kidney disease more often in people with end-stage kidney disease. Some other possible causes of hyperphosphatemia includes diabetic ...

Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require ...

Red meat, long acclaimed for its richness in protein, iron and vitamin B12, is now at the heart of numerous debates ...

The global hyperphosphatemia market is expected to reach US$ 20.24 billion by 2033, growing at a CAGR of 4.8%. Iron-based phosphate binder is expected to grab 20% of the hyperphosphatemia market by ...

Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Akebia Therapeutics, Inc, Vifor Pharma Management Ltd. , Lupin Limited, ...